ClinVar Miner

Submissions for variant NM_147127.5(EVC2):c.534dup (p.Glu179Ter)

dbSNP: rs1553851462
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000674426 SCV005381646 pathogenic Ellis-van Creveld syndrome 2024-08-01 criteria provided, single submitter clinical testing Variant summary: EVC2 c.534dupT (p.Glu179X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 251446 control chromosomes. To our knowledge, no occurrence of c.534dupT in individuals affected with EVC2-related conditions has been reported. ClinVar contains an entry for this variant (Variation ID: 558195). Based on the evidence outlined above, the variant was classified as pathogenic for autosomal recessive Ellis-van Creveld syndrome.
Ambry Genetics RCV002532163 SCV003536789 pathogenic Inborn genetic diseases 2021-10-08 criteria provided, single submitter clinical testing The c.534dupT (p.E179*) alteration, located in exon 5 (coding exon 5) of the EVC2 gene, consists of a duplication of T at position 534, causing a translational frameshift with a predicted alternate stop codon after amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on the supporting evidence, this variant is expected to be causative of autosomal recessive Ellis-van Creveld syndrome (AR); however, its clinical significance for autosomal dominant Weyers acrofacial dysostosis (AD) is unclear. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). Based on the available evidence, this alteration is classified as pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV001861843 SCV002123097 pathogenic Ellis-van Creveld syndrome; Curry-Hall syndrome 2024-11-07 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Glu179*) in the EVC2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EVC2 are known to be pathogenic (PMID: 17024374, 19810119, 19876929). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with EVC2-related conditions. ClinVar contains an entry for this variant (Variation ID: 558195). For these reasons, this variant has been classified as Pathogenic.
Counsyl RCV000674426 SCV000799762 likely pathogenic Ellis-van Creveld syndrome 2018-05-04 no assertion criteria provided clinical testing This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. The submitted information has not been verified. If you have questions about the information contained on this website, please see a health care professional.